Natural Product (NP) Details
| General Information of the NP (ID: NP9453) | |||||
|---|---|---|---|---|---|
| Name |
Schisandrol A
|
||||
| Synonyms |
Schisandrin; Schizandrin; Schizandrol A; 7432-28-2; Wuweizichun A; Wuweizi alcohol A; Schisandrol A; (+)-Schizandrin; 3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaen-9-ol; Schisandrine; MFCD00905761; Schisandrin,(S); SCHEMBL2702845; CHEBI:80900; DTXSID20995843; AKOS015918158; 1,2,3,10,11,12-hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulen-6-ol; AS-17718; DB-055861; FT-0630370; N1884; V1514; C17064; 432S282; Q-100805; 1,2,3,10,11,12-Hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cycloocten-6-ol #; Dibenzo(a,c)cycloocten-6-ol, 5,6,7,8-tetrahydro-6,7-dimethyl-1,2 3,10,11,12-hexamethoxy-,stereoisomer
Click to Show/Hide
|
||||
| Species Origin | Schisandra chinensis ... | Click to Show/Hide | |||
| Schisandra chinensis | |||||
| Disease | Hepatocellular carcinoma [ICD-11: 2C12] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.58
MDCK Permeability
-4.566
PAMPA
- - -
HIA
- - -
Distribution
VDss
0.127
PPB
82.1%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
+++
CYP2C19 inhibitor
- - -
CYP2C19 substrate
+++
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
-
CYP3A4 inhibitor
+
CYP3A4 substrate
+++
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
++
HLM Stability
- - -
Excretion
CLplasma
5.522
T1/2
1.137
Toxicity
DILI
-
Rat Oral Acute Toxicity
- -
FDAMDD
+
Respiratory
+
Human Hepatotoxicity
+
Ototoxicity
+
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
+
Hematotoxicity
-
Genotoxicity
- - -
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C24H32O7
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3CC1(C)O)OC)OC)OC)OC)OC)OC
|
||||
| InChI |
1S/C24H32O7/c1-13-9-14-10-16(26-3)20(28-5)22(30-7)18(14)19-15(12-24(13,2)25)11-17(27-4)21(29-6)23(19)31-8/h10-11,13,25H,9,12H2,1-8H3
|
||||
| InChIKey |
YEFOAORQXAOVJQ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 7432-28-2
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
SCH acts by affecting the normal formation and functioning of the Pgp-substrate complexes. | |||||